Drug Profile
Frexalimab - ImmuNext/Sanofi
Alternative Names: INX 021; SAR-441344Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator ImmuNext
- Developer Sanofi
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple sclerosis
- Phase II Sjogren's syndrome; Systemic lupus erythematosus; Type 1 diabetes mellitus
Most Recent Events
- 17 Apr 2024 Long term efficacy and adverse events data from phase-II trial in Multiple sclerosis released by Sanofi
- 19 Feb 2024 Sanofi announces intention to submit an application to the regulatory body for Multiple sclerosis (SC, IV), in 2026 or beyond (Sanofi pipeline, February 2024)
- 15 Feb 2024 Efficacy data from a phase II trial in Multiple sclerosis released by Sanofi